Cardio3

  • Cardio3 BioSciences floated on Euronext Brussels and Euronext Paris
  • Proceeds of the IPO were dedicated to fund European phase III trials of its flagship product, C-Cure
  • Kempen & Co acted as Sole Global Coordinator and Joint Bookrunner